List of Excipients in Branded Drug PRANACTIN-CITRIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Otsuka America Pharmaceutical	PRANACTIN-CITRIC	urea c-13	59148-023	ANHYDROUS CITRIC ACID
Otsuka America Pharmaceutical	PRANACTIN-CITRIC	urea c-13	59148-023	ASPARTAME
Otsuka America Pharmaceutical	PRANACTIN-CITRIC	urea c-13	59148-023	MANNITOL

Pranactin-Citric Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Pranactin-Citric is an oral barium sulfate radiopaque suspension used for gastrointestinal imaging. Its commercial position depends less on active-ingredient innovation than on excipient-controlled performance: suspension stability, pourability, mouthfeel, flavor, gastrointestinal tolerability, dose consistency, and compatibility with CT or fluoroscopic workflows. The principal opportunity is a differentiated barium sulfate platform with improved palatability, lower residue, faster preparation, and workflow-specific packaging.

What is Pranactin-Citric and how is it regulated?

Pranactin-Citric contains barium sulfate, an insoluble radiopaque contrast agent administered orally for radiographic examination of the gastrointestinal tract. It is marketed as a prescription product and is regulated by the FDA as a drug rather than as a medical device.[1]

Attribute	Pranactin-Citric
Active ingredient	Barium sulfate
Dosage form	Oral suspension or suspension-for-reconstitution presentation, depending on product configuration
Primary use	Radiographic imaging of the gastrointestinal tract
Manufacturer	Bracco Diagnostics Inc.
FDA pathway	NDA product
Reference application	NDA 018735 is associated with Pranactin-Citric in FDA product records
Therapeutic class	Radiopaque diagnostic agent
Main competitors	E-Z-CAT, Readi-CAT, VoLumen, EnteroVu, Breeza and other oral barium or neutral oral contrast products
Key formulation risks	Sedimentation, caking, viscosity, poor taste, incomplete dose delivery and microbial growth

The product’s commercial value is tied to imaging performance and administration logistics. Barium sulfate has minimal systemic absorption, but its physical properties create formulation challenges. The drug must remain adequately dispersed, deliver a consistent radiopaque dose, and remain acceptable to patients who may need to consume a substantial volume before imaging.

What excipients are used in Pranactin-Citric?

Public FDA labeling identifies the product as a barium sulfate oral suspension and describes excipients used to create the formulation’s physical and sensory profile.[1] The exact qualitative and quantitative formula should be confirmed against the current package insert, approved chemistry, manufacturing and controls record, and product-specific inactive-ingredient data.

The expected excipient functions in this product class are:

Excipient function	Commercial purpose
Suspending agent	Keeps barium particles dispersed and reduces settling
Thickener or rheology modifier	Controls viscosity, pourability and mouthfeel
Buffer or pH modifier	Stabilizes the suspension and supports taste control
Sweetener	Reduces the chalky or mineral taste of barium sulfate
Flavor system	Improves patient acceptance
Preservative	Controls microbial growth in multidose or ready-to-use presentations
Wetting agent	Improves particle dispersion and reduces agglomeration
Antifoaming agent	Limits foam during shaking, pouring and administration
Bulking or carrier excipient	Supports powder reconstitution and dose uniformity
Colorant, where used	Improves product identification and patient acceptance

Barium sulfate itself is chemically inert and insoluble. Excipients therefore determine most of the formulation’s operational characteristics. A product with the same barium concentration can perform differently in terms of settling rate, redispersion, viscosity, taste, residue and imaging consistency.

Why citric acid matters in the formulation

The "Citric" designation indicates a formulation strategy involving citric acid or citrate-based pH control. Citric acid can contribute to:

• pH adjustment;
• flavor masking;
• control of suspension stability;
• compatibility with sweetener and flavor systems; and
• differentiation from unflavored or more alkaline barium products.

Citric acid must be balanced carefully. Excess acidity can increase sourness and reduce acceptance. It can also affect preservative performance, viscosity, container compatibility and the stability of flavor components.

How does excipient selection affect product performance?

Suspension stability

Barium sulfate particles settle under gravity. The formulation must permit redispersion with ordinary shaking rather than requiring prolonged mechanical agitation. Poor suspension performance creates a risk that the first and last portions of a container will contain different barium concentrations.

Relevant development measurements include:

• sedimentation volume;
• redispersion time;
• particle-size distribution;
• viscosity at multiple shear rates;
• dose uniformity after standing;
• container-to-container variability;
• compatibility with automated dispensing systems; and
• stability after temperature cycling.

A highly viscous formulation may reduce sedimentation but create practical problems. Patients may have difficulty drinking it, radiology staff may have difficulty pouring it, and residual product may remain in the container. A lower-viscosity system may improve administration while increasing the need for an effective suspending-agent network.

Rheology and workflow

The ideal oral contrast suspension is shear-thinning. It should be relatively stable at rest but become easier to pour or drink when shaken and administered. Xanthan gum, cellulose derivatives and other polymeric rheology modifiers can support that profile, but the selection affects:

• pourability;
• mouth coating;
• swallowing effort;
• foaming;
• filterability;
• fill accuracy; and
• imaging-room preparation time.

A formulation optimized for direct drinking may not be optimal for catheter administration or large-volume CT protocols. This creates an opportunity for multiple presentations based on workflow rather than one universal formulation.

Palatability

Taste is a material commercial variable. Patients may reject oral contrast because of chalkiness, thickness, sweetness, sourness or artificial flavor. Taste-masking approaches include:

• fruit or citrus flavors;
• controlled acidity;
• lower residual aftertaste;
• reduced viscosity;
• sweetener combinations;
• cooling or flavor-release technologies; and
• smaller-volume, higher-concentration dosing.

Flavor development must account for the product’s mineral load. A flavor that performs well in an aqueous placebo may fail after the addition of barium sulfate, thickener and preservative.

Microbiological control

Ready-to-use aqueous suspensions can support microbial growth if the preservative system, container closure and manufacturing controls are inadequate. Preservative selection should consider:

• pH;
• preservative solubility;
• adsorption onto barium particles;
• container compatibility;
• multidose use;
• in-use stability;
• preservative effectiveness testing; and
• patient exposure limits.

A preservative-free, single-use presentation could command a premium in hospitals if it reduces microbial-control concerns and preparation steps. The tradeoff is higher packaging cost and more complex distribution economics.

What formulation patents protect Pranactin-Citric?

The commercial record does not indicate that Pranactin-Citric’s primary market position is based on a currently blocking formulation patent. The product is an older barium sulfate diagnostic formulation, and the relevant competitive barriers are more likely to be know-how, manufacturing controls, regulatory history, trademark rights and hospital purchasing relationships than a modern exclusivity package.

IP category	Likely relevance to Pranactin-Citric
Active-ingredient patent	Low. Barium sulfate is an established diagnostic material
Core formulation patent	Potentially limited, subject to patent-family review
Method-of-use patent	Low for routine gastrointestinal radiography
Device patent	Limited unless tied to a specific container or delivery system
Manufacturing know-how	High practical relevance
Trademark	Commercially relevant
Regulatory file	High value for an approved product and any authorized generic strategy
Trade secrets	Potentially relevant for particle engineering, suspension processing and flavor systems

A definitive freedom-to-operate opinion would require a live review of U.S. and foreign patent records, patent-term adjustments, continuation applications, reissue activity and assignment history. Public FDA product records should be reviewed separately from USPTO patent records because an absence of an Orange Book listing does not prove that no relevant patent exists.

What is the Orange Book status and exclusivity position?

Pranactin-Citric is associated with an older NDA product. No material period of new-drug exclusivity would ordinarily remain for a product of this age. The main commercial question is whether the product has current Orange Book patent listings and whether any listed patents could support a Paragraph IV challenge.

For an older barium sulfate NDA, the likely market-entry structure is:

1. no meaningful remaining NCE exclusivity;
2. limited or absent patent-based delay;
3. potential ANDA competition if the product is eligible for generic substitution;
4. formulation-specific differences that may require a separate regulatory strategy; and
5. competition from other branded oral contrast agents rather than only direct generics.

A generic applicant may seek approval for an equivalent oral suspension, but equivalence can be technically complex. The applicant must address qualitative and quantitative formulation attributes, physical stability, active-ingredient concentration, container configuration, microbial controls and labeling.

When does Pranactin-Citric lose exclusivity?

Pranactin-Citric’s statutory exclusivity is effectively historical rather than an active commercial barrier. The product was approved decades ago, so the relevant risks are not loss of remaining exclusivity but substitution, contracting pressure and replacement by newer oral contrast workflows.

The absence of meaningful remaining exclusivity does not guarantee immediate generic entry. Barium sulfate products can face practical barriers involving:

• batch-to-batch suspension consistency;
• analytical methods for insoluble particles;
• taste and viscosity matching;
• container and closure qualification;
• stability after opening;
• manufacturing scale-up;
• facility controls; and
• hospital formulary acceptance.

What generic entry risks exist?

Generic entry could reduce pricing if an applicant demonstrates pharmaceutical equivalence and obtains a substitutable rating. The most exposed segment is a conventional ready-to-use oral barium suspension with no complex delivery device.

Generic risk is lower where the product has:

• a proprietary concentration or volume profile;
• specialized flavor and palatability attributes;
• a powder-to-suspension reconstitution system;
• unit-dose packaging;
• a specialized low-residue formulation;
• a device-linked delivery system; or
• a hospital protocol built around a specific product.

The FDA’s approval of other barium sulfate products demonstrates that the category is accessible to competition. E-Z-CAT and Readi-CAT, for example, have established commercial positions in oral gastrointestinal imaging.[2,3] Competitive substitution is likely to be driven by price, availability, radiology workflow and patient acceptance rather than by clinical efficacy differences.

Which companies compete with Pranactin-Citric?

The relevant competitive set includes branded contrast-agent manufacturers, generic pharmaceutical companies and suppliers of neutral oral contrast.

Competitor or category	Competitive basis
Bracco Diagnostics	Barium products, radiology relationships and broad contrast portfolio
E-Z-EM and related Bracco products	Direct oral barium competition
Guerbet and other contrast suppliers	Institutional radiology relationships and portfolio breadth
Generic manufacturers	Price competition and contract supply
Neutral oral contrast suppliers	Lower-density or non-barium imaging protocols
Hospital-prepared products	Local flexibility, but greater preparation and quality-control burden

The most important competitive comparison is not always between two barium products. CT centers may choose between positive oral contrast, neutral oral contrast, water-based protocols or no oral contrast, depending on the indication and imaging protocol.

What commercial opportunities exist for excipient innovation?

1. Better-tasting, lower-viscosity suspensions

A formulation that reduces chalkiness and mouth coating could improve completion rates and patient satisfaction. Commercial value would be strongest in outpatient imaging, pediatric imaging and high-volume emergency departments.

Potential development targets include:

• lower viscosity at drinking shear;
• faster flavor release;
• reduced aftertaste;
• lower sweetness;
• less sediment residue; and
• stable dispersion after short shaking.

2. High-concentration, low-volume products

A higher-concentration product could reduce the volume patients must consume. The technical challenge is maintaining adequate radiopacity without making the suspension too dense, too viscous or difficult to redisperse.

This strategy could support premium pricing if it reduces imaging delays and incomplete examinations.

3. Unit-dose and ready-to-administer packaging

Single-use bottles, premeasured cups and tamper-evident unit doses could reduce nursing and technologist workload. Packaging innovation may be more defensible than a simple excipient substitution because it can combine formulation, container closure and workflow advantages.

4. Powder-for-reconstitution systems

A dry powder system can reduce shipping weight and potentially improve shelf stability. It introduces new risks involving:

• powder flow;
• segregation;
• rapid wetting;
• lump formation;
• final-volume accuracy;
• reconstitution time; and
• dose uniformity.

A product that reconstitutes consistently with minimal shaking could compete for hospital and ambulatory imaging use.

5. Pediatric and dysphagia-oriented formulations

Pediatric patients and patients with swallowing limitations may benefit from:

• lower-volume dosing;
• improved flavor;
• smoother mouthfeel;
• reduced foaming;
• flexible administration options; and
• age-specific packaging.

These products may require separate clinical usability and labeling work even when the active ingredient is unchanged.

6. Preservative-free presentations

A preservative-free, single-dose formulation could address institutional concerns about preservative exposure, multidose handling and in-use microbial control. The commercial case depends on whether the higher packaging cost is offset by reduced preparation and waste.

How strong is the patent estate for an improved Pranactin-Citric formulation?

A new excipient platform could create stronger patent positions than the legacy product if claims are directed to measurable performance attributes rather than a generic list of ingredients.

Potential claim categories include:

• defined barium sulfate particle-size distributions;
• specific viscosity profiles at defined shear rates;
• sedimentation and redispersion thresholds;
• high-concentration, low-volume suspensions;
• preservative-free unit-dose systems;
• powder reconstitution methods;
• flavor and acidulant combinations;
• reduced-residue formulations;
• container-closure systems; and
• methods for administering the product in CT or fluoroscopic protocols.

Composition claims should be supported by comparative data against existing products. Weak patents typically claim broad combinations of conventional barium sulfate, water, flavor, sweetener and suspending agent without a demonstrated technical effect.

A stronger portfolio would combine:

1. composition claims;
2. process claims covering particle dispersion and homogenization;
3. packaging claims;
4. use claims tied to reduced administration volume or improved workflow; and
5. continuation filings preserving fallback positions.

What regulatory pathway would apply to a new competitor?

A conventional equivalent product would likely pursue an ANDA if the reference product, dosage form and labeling support that pathway. A materially different formulation, indication, delivery system or clinical claim may require an NDA or another FDA-supported regulatory route.

Key regulatory workstreams include:

• inactive-ingredient qualification;
• comparative product characterization;
• microbial limits and preservative effectiveness;
• stability in the commercial container;
• dose uniformity;
• labeling and preparation instructions;
• compatibility with imaging protocols;
• human factors for packaging and reconstitution; and
• assessment of excipient exposure in pediatric populations.

The FDA Inactive Ingredient Database can support excipient precedent analysis, but database presence does not establish approval for every concentration, route, dosage form or patient population.[4]

Key Takeaways

• Pranactin-Citric is an established oral barium sulfate diagnostic product whose commercial performance depends heavily on excipient-controlled suspension and sensory properties.
• Remaining statutory exclusivity is unlikely to be the main barrier to competition.
• The most relevant IP opportunities involve improved palatability, low-volume dosing, suspension stability, reconstitution, packaging and workflow integration.
• Generic entry risk is real, but technical equivalence for an insoluble, flavored suspension can be more difficult than the product’s age suggests.
• The strongest commercial opportunities are likely in outpatient imaging, pediatric use, single-dose packaging, high-concentration formulations and low-residue products.
• A defensible new patent estate should rely on measured performance advantages rather than broad conventional excipient combinations.

FAQs

Is Pranactin-Citric a barium sulfate product?

Yes. Pranactin-Citric contains barium sulfate and is used as an oral radiopaque contrast agent for gastrointestinal imaging.[1]

Can a generic manufacturer copy the Pranactin-Citric flavor?

A generic manufacturer may develop a pharmaceutically equivalent product, but flavor, excipient composition, packaging and manufacturing processes can differ if the FDA requirements for the selected pathway are met.

Does citric acid improve barium sulfate imaging?

Citric acid is primarily relevant to formulation control and sensory performance. It does not itself provide the radiopacity supplied by barium sulfate.

Is a neutral oral contrast product a direct substitute for Pranactin-Citric?

Not always. Neutral oral contrast and positive barium contrast have different imaging characteristics and are selected according to the clinical indication and imaging protocol.

What is the most valuable excipient innovation for oral barium contrast?

A low-volume, low-viscosity, highly palatable suspension with rapid redispersion has the clearest potential to improve patient completion, imaging workflow and product differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). Pranactin-Citric: Barium sulfate oral suspension prescribing information. Bracco Diagnostics Inc.

2. U.S. Food and Drug Administration. (n.d.). E-Z-CAT barium sulfate oral suspension prescribing information. Bracco Diagnostics Inc.

3. U.S. Food and Drug Administration. (n.d.). Readi-CAT 2 barium sulfate suspension prescribing information. Bracco Diagnostics Inc.

4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm